Avecho signs $23 million deal with Sandoz for CBD insomnia treatment
Avecho Biotechnology signed an exclusive ten-year development and licensing agreement with Sandoz for the commercial rights to its cannabidiol (CBD) insomnia treatment in Australia, according to an ASX announcement released on Monday. The deal includes an upfront payment of US$3 million (approximately A$4.8 million) and potential development milestone payments totalling US$16 million prior to commercialisation.…
